FDA approves Roche's giredestrant pill for ESR1-mutated advanced breast cancer
Taken with everolimus, the once-daily pill nearly doubled the time before tumors worsened in a trial. Its list price will be about $270,000 a year.

Key Takeaways
- Only adults whose tumors carry an ESR1 mutation qualify, identified with a newly authorized blood test.
- Median time before the cancer worsened was 10 months, versus 5.5 months on standard hormone therapy plus everolimus.
- The FDA said it is too early to know whether the combination helps patients live longer.
- A separate FDA decision on use in early-stage breast cancer is expected by Nov. 30.
The Food and Drug Administration on Monday approved giredestrant, a once-daily pill from Roche, for adults with advanced breast cancer that keeps growing despite hormone therapy and carries a mutation in the ESR1 gene. The drug, sold under the brand name Wilserdly, is approved for use together with everolimus, an older cancer medicine.
The approval applies to estrogen receptor-positive, HER2-negative breast cancer that has invaded nearby tissue or spread elsewhere in the body. This is the most common broad type of breast cancer. To qualify, patients must have had their disease come back or progress after earlier hormone treatment.
Tumors in this group use estrogen as fuel, which is why drugs that block or lower the hormone are the backbone of treatment. Many tumors eventually acquire changes in ESR1, the gene behind the estrogen receptor, and those changes let them keep growing despite standard hormone drugs. Roche said such mutations show up in as many as 40% of patients with this form of advanced disease.
To find eligible patients, the FDA also authorized a blood test, FoundationOne Liquid CDx, which detects fragments of tumor DNA circulating in the bloodstream. That approach looks practical. ESR1 mutations often appear only after years of treatment, and a blood draw is far easier to repeat than a biopsy of a tumor that has spread.
What the trial showed
The approval rests on a study of 373 adults with this type of breast cancer whose disease had worsened after prior therapy. Of those, 207 had ESR1 mutations. Every participant took everolimus, paired with either giredestrant or a standard hormone therapy their doctor selected.
In patients with the mutation, the giredestrant group went a median of 10 months before their cancer progressed, compared with 5.5 months in the comparison group. A median of 10 months means half of patients stayed progression-free for less time than that and half for longer. Tumors shrank in 27% of patients on giredestrant, about double the 14% rate in the other arm.
The trial design makes those numbers more convincing. Because both groups received everolimus, the gap reflects the choice of hormone partner rather than an extra drug piled on in one arm. Nearly doubling the time before progression is a sizable margin for patients whose earlier hormone treatments have already stopped working.
The data leave one important gap. The FDA noted that it is still too early to say whether the combination extends survival. Delaying tumor growth is a meaningful benefit, but it is not the same as living longer, and later results will need to show whether the two go together.
Dr. Erica Mayer, who directs breast cancer clinical research at the Dana-Farber Cancer Institute in Boston, said in Roche's announcement that patients whose disease is advancing on hormone treatments face "difficult choices and deteriorating quality of life as options narrow."
Side effects, cost and a larger decision ahead
The recommended dose is 30 milligrams once a day, taken with or without food. The most common side effects of the combination were inflammation of the mouth or lungs, rash, fatigue, diarrhea, muscle and bone pain, and nausea. Some patients also had abnormal blood test results. The prescribing label carries warnings about an abnormally slow heartbeat, known as bradycardia, and about possible harm to a developing embryo or fetus.
Mouth sores and lung inflammation are well-known problems with everolimus, so some of that side-effect profile likely reflects the partner drug rather than giredestrant itself. The trial results as reported don't separate the two, and the heart-rate warning is specific enough that it will deserve attention in practice.
Roche told STAT the list price will be about $270,000 a year, and patients will also take everolimus. List prices usually differ from what insurers and patients actually pay, but that figure means coverage decisions will largely determine how many eligible patients get the drug.
Giredestrant is not the first pill of its kind. It belongs to a class of drugs that block estrogen receptors and cause them to break down. That class previously included mainly fulvestrant, which is given as an injection, until the FDA approved Menarini's oral drug elacestrant in 2023 for ESR1-mutated advanced breast cancer. Roche's approval stands out for the pairing with everolimus, which lets doctors target two separate growth pathways at once: giredestrant shuts down the estrogen receptor, while everolimus blocks a different route cancer cells use to grow.
The next decision may matter more for the drug's reach. The FDA is expected to rule by Nov. 30 on whether giredestrant can be used after surgery in people with early-stage breast cancer who face a higher risk of recurrence. That population is much larger than the group of patients with advanced, ESR1-mutated disease covered by Monday's approval.
Roche has said giredestrant could become its best-selling product ever. According to STAT, analysts expect billions of dollars in annual sales if the drug wins approval for other types of breast cancer, with peak estimates ranging from a few billion dollars a year to more than $10 billion.
For patients already living with metastatic disease, the question that matters most is the one the FDA left open: whether the extra months before their cancer progresses will eventually translate into longer lives.




